REFERENCES
2. Wallin A, Román GC, Esiri M, Kettunen P, Svensson J, et al. Update on vascular cognitive impairment associated with subcortical small-vessel disease. J Alzheimers Dis 2018;62:1417-41.
4. Karageorgiou E, Miller BL. Frontotemporal lobar degeneration: a clinical approach. Semin Neurol 2014;34:189-201.
5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939-44.
6. Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, et al. Research evaluation and diagnosis of probable Alzheimer’s disease over the last two decades: I. Neurology 2000;55:1854-62.
7. Risse SC, Raskind MA, Nochlin D, Sumi SM, Lampe TH, et al. Neuropathological findings in patients with clinical diagnoses of probable Alzheimer’s disease. Am J Psychiatry 1990;147:168-71.
8. Mendez M, Mastri AR, Sung JH, Frey WH. Clinically diagnosed Alzheimer’s disease: neuropathologic findings in 650 cases. Alzheimer Dis Assoc Disord 1992;6:35-43.
9. Gilleard CJ, Kellett JM, Coles JA, Millard PH, Honavar M, et al. The St. George’s dementia bed investigation study: a comparison of clinical and pathological diagnosis. Acta Psychiatr Scand 1992;85:264-69.
10. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263-69.
11. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;13:614-29.
12. Paraskevas GP, Kaselimis D, Kourtidou E, Constantinides V, Bougea A, et al. Cerebrospinal fluid biomarkers as a diagnostic tool of the underlying pathology of primary progressive aphasia. J Alzheimers Dis 2017;55:1453-61.
13. Constantinides VC, Paraskevas GP, Emmanouilidou E, Petropoulou O, Bougea A, et al. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. J Neurol Sci 2017;382:91-5.
14. Constantinides VC, Paraskevas GP, Efthymiopoulou E, Stefanis L, Kapaki E. Clinical, neuropsychological and imaging characteristics of Alzheimer’s disease patients presenting as corticobasal syndrome. J Neurol Sci 2019;398:142-7.
15. Paraskevas GP, Constantinides VC, Pyrgelis ES, Kapaki E. Mixed small vessel disease in a patient with dementia with Lewy bodies. Brain Sci 2019;9:E159.
16. Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, et al. Alzheimer’s disease-subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. J Cereb Blood Flow Metab 2016;36:95-113.
17. Peavy GM, Edland SD, Toole BM, Hansen LA, Galasko DR, et al. Phenotypic differences based on staging of Alzheimer’s neuropathology in autopsy-confirmed dementia with Lewy bodies. Parkinsonism Relat Disord 2016;31:72-8.
18. van der Zande JJ, Steenwijk MD, Ten Kate M, Wattjes MP, Scheltens P, et al. Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer’s disease pathology. Neurobiol Aging 2018;71:171-8.
19. Savica R, Beach TG, Hentz JG, Sabbagh MN, Serrano GE, et al. Lewy body pathology in Alzheimer’s disease: A clinicopathological prospective study. Acta Neurol Scand 2019;139:76-81.
20. Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, et al. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2017;88:113-8.
21. Bennett D, Schneider J, Bienias J, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer pathology and cerebral infarctions. Neurology 2005;64:834-41.
22. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, et al. Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch Neurol 1994;51:888-95.
23. Johnell K, Religa D, Eriksdotter M. Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients. Dement Geriatr Cogn Disord 2013;35:239-48.
24. Jellinger KA, Bancher C. Neuropathology of Alzheimer’s disease: a critical update. J Neural Transm Suppl 1998;54:77-95.
25. Bancher C, Paulus W, Paukner K, Jellinger K. Neuropathologic diagnosis of Alzheimer disease: consensus between practicing neuropathologists? Alzheimer Dis Assoc Disord 1997;11:207-19.
27. Iqbal K, Alonso A, Gong C, Khatoon S, Kudo T, et al. Molecular pathology of Alzheimer neurofibrillary degeneration. Acta Neurobiol Exp (Wars) 1993;53:325-35.
28. Choi BH. Oxidative stress and Alzheimer’s disease. Neurobiol Aging 1995;16:675-8.
29. Smith-Swintosky VL, Mattson MP. Glutamate, beta-amyloid precursor proteins, and calcium mediated neurofibrillary degeneration. J Neural Transm Suppl 1994;44:29-45.
31. Gonzalez B, Abud EM, Abud AM, Poon WW, Gylys KH. Tau spread, apolipoprotein e, inflammation, and more: rapidly evolving basic science in Alzheimer disease. Neurol Clin 2017;35:175-90.
32. Rietdijk CD, van Wezel RJA, Garssen J, Kraneveld AD. Neuronal toll-like receptors and neuro-immunity in Parkinson’s disease, Alzheimer’s disease and stroke. Neuroimmunol Neuroinflammation 2016;3:27-37.
33. Burns LH, Wang HY. Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer’s disease. Neuroimmunol Neuroinflammation 2017;4:263-71.
34. Rentzos M, Zoga M, Paraskevas GP, Kapaki E, Rombos A, et al. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal dementia. J Geriatr Psychiatry Neurol 2006;19:114-7.
35. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, et al. Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-34.
36. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
37. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-58.
38. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231-45.
39. Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer’s disease and dementia with Lewy bodies. Clin Chem Lab Med 2006;44:1472-80.
40. Sjögren M, Minthon L, Davidsson P, Granérus AK, Clarberg A, et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm (Vienna) 2000;107:563-79.
41. Paraskevas GP, Kapaki E, Liappas I, Theotoka I, Mamali I, et al. The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. J Geriatr Psychiatry Neurol 2005;18:163-73.
42. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-62.
43. Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer’s disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol 2003;10:119-28.
44. Paraskevas GP, Kapaki E, Papageorgiou SG, Kalfakis N, Andreadou E, et al. CSF biomarker profile and diagnostic value in vascular dementia. Eur J Neurol 2009;16:205-11.
46. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci Transl Med 2014;6:226ra30.
47. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, et al. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012;69:98-106.
48. Park JE, Choi KY, Kim BC, Choi SM, Song MK, et al. Cerebrospinal fluid biomarkers for the diagnosis of prodromal Alzheimer’s disease in amnestic mild cognitive impairment. Dement Geriatr Cogn Dis Extra 2019;9:100-13.
49. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer’s disease. PLoS One 2009;4:e6294.
50. Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement 2017;13:274-84.
51. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-34.
52. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008;29:1143-59.
53. Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, et al. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer’s disease from other dementias and healthy controls in the OPTIMA cohort. J Alzheimers Dis 2015;44:525-39.
54. Kapaki E, Liappas I, Paraskevas GP, Theotoka I, Rabavilas A. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer’s disease in the early stages. Int J Geriatr Psychiatry 2005;20:722-9.
55. Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, et al. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging 2010;31:1867-76.
56. Kapaki E, Paraskevas GP, Papageorgiou SG, Bonakis A, Kalfakis N, et al. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 2008;22:47-53.
57. Wallin A, Kapaki E, Boban M, Engelborghs S, Hermann DM, et al. Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report. BMC Neurol 2017;17:102.
58. Paraskevas GP, Bougea A, Constantinides VC, Bourbouli M, Petropoulou O, et al. In vivo prevalence of Alzheimer biomarkers in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2019;47:289-96.
59. Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, et al. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer’s disease. Eur J Neurol 2007;14:168-73.
60. Ossenkoppele R, Mattsson N, Teunissen CE, Barkhof F, Pijnenburg Y, et al. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer’s disease. Neurobiol Aging 2015;36:2340-47.
61. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Consensus report of the working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. Neurobiol Aging 1998;19:109-16.
62. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-9.
63. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1-26.
64. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:270-9.
65. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:280-92.
66. Lewczuk P, Riederer P, O’Bryant SE, Verbeek MM, Dubois B, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry 2018;19:244-328.
67. Blennow K, Zetterberg H. The past and the future of Alzheimer’s disease fluid biomarkers. J Alzheimers Dis 2018;62:1125-40.
68. Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, et al. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol 2018;136:821-53.
69. Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, et al. Qualification opinion of novel methodologies in the predementia stage of Alzheimer’s disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden-regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. Eur Neuropsychopharmacol 2011;21:781-8.
70. Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, et al. The road ahead to cure Alzheimer’s disease: development of biological markers and Neuroimaging methods for prevention trials across all stages and target populations. J Prev Alzheimers Dis 2014;1:181-202.
72. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J. Amyloid b 42/40 CSF concentration ratio in the diagnostics of Alzheimer’s disease: validation of two novel assays. J Alzheimers Dis 2015;43:183-91.
73. Jack CR Jr, Knopman DS, Chételat G, Dickson D, Fagan AM, et al. Suspected non-Alzheimer disease pathophysiology–concept and controversy. Nat Rev Neurol 2016;12:117-24.
74. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018;14:535-62.
75. van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, et al. Cerebrospinal fluid Alzheimer’s disease biomarkers across the spectrum of Lewy body diseases: results from a large multicenter cohort. J Alzheimers Dis 2016;54:287-95.
76. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017;89:88-100.
77. Skogseth R, Hortobágyi T, Soennesyn H, Chwiszczuk L, Ffytche D, et al. Accuracy of clinical diagnosis of dementia with Lewy bodies versus neuropathology. J Alzheimers Dis 2017;59:1139-52.
78. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-77.
79. Lleó A, Irwin DJ, Illán-Gala I, McMillan CT, Wolk DA, et al. A 2-Step Cerebrospinal algorithm for the selection of frontotemporal lobar degeneration subtypes. JAMA Neurol 2018;75:738-45.
80. Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J. Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J Neural Transm 2009;116:1163-7.
81. Lewczuk P, Kornhuber J, Toledo JB, Trojanowski JQ, Knapik-Czajka M, et al. Validation of the Erlangen score algorithm for the prediction of the development of dementia due to Alzheimer’s disease in pre-dementia subjects. J Alzheimers Dis 2015;48:433-41.
82. Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid β(1-42), tau, and phosphorylated tau in Alzheimer’s disease: report of an international workshop. Int J Alzheimers Dis 2010;2010:635053.
83. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, et al. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011;7:386-95.e6.
84. Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers. Clin Chem 2013;59:903-16.
85. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, et al; Alzheimer’s Association QC Program Work Group. CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement 2013;9:251-61.
86. Vos SJ, Visser PJ, Verhey F, Aalten P, Knol D, et al. Variability of CSF Alzheimer’s disease biomarkers: implications for clinical practice. PLoS One 2014;9:e100784.
87. Biomarkers for Alzheimer’s disease and Parkinson’s disease project of the Joint Programming Neurodegenerative Disease (JPND-BIOMARKAPD) 2012. Available from: http://www.neurodegenerationresearch.eu/fileadmin/Project_Fact_Sheets/PDFs/Biomarkers/BIOMARKAPD_Fact_Sheet_Template.pdf [Last accessed on 15 May 2020].
88. Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement 2017;8:111-26.
89. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012;6:419-30.
90. Le Bastard N, De Deyn PP, Engelborghs S. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem 2015;61:734-43.
91. Bourbouli M, Kapaki E, Petropoulou O, Paraskevas GP. Improved Performance of CSF dementia biomarker measurements over time: the effect of quality control and harmonization programs. Biomark Applic 2018:BMAP-126.
92. Niemantsverdriet E, Goossens J, Struyfs H, Martin JJ, Goeman J, et al. Diagnostic impact of cerebrospinal fluid biomarker (pre-)analytical variability in Alzheimer’s disease. J Alzheimers Dis 2016;51:97-106.
93. Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, et al. Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clin Biochem 2019;72:30-8.
94. Junttila A, Kuvaja M, Hartikainen P, Siloaho M, Helisalmi S, et al. Cerebrospinal fluid TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis patients with and without the C9ORF72 hexanucleotide expansion. Dement Geriatr Cogn Dis Extra 2016;6:142-9.
95. Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides VC, et al. Cerebrospinal fluid TAR DNA-binding protein 43 combined with Tau proteins as a candidate biomarker for amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders. Dement Geriatr Cogn Disord 2017;44:144-52.
96. Paraskevas GP, Bourbouli M, Zaganas I, Kapaki E. The emerging TDP-43 proteinopathy. Neuroimmunol Neuroinflammation 2018;5:17.
97. Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dementia 2015;1:505-12.
98. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010;4:683-99.
99. Schade S, Mollenhauer B. Biomarkers in biological fluids for dementia with Lewy bodies. Alzheimers Res Ther 2014;6:72.
100. Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, et al. Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer’s disease patients and control subjects. Dement Geriatr Cogn Disord 2011;31:413-6.
101. Aarsland D, Kurz M, Beyer M, Bronnick K, Piepenstock Nore S, et al. Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers. Dement Geriatr Cogn Disord 2008;25:195-205.
102. Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K. The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer’s disease. PLoS One 2013;8:e81654.
103. Bougea A, Stefanis L, Paraskevas GP, Emmanouilidou E, Efthymiopoulou E, et al. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson’s disease dementia, dementia with Lewy bodies and Alzheimer’s disease. J Neurol 2018;265:2295-301.
104. Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther 2014;6:25.
105. Simonsen AH, Kuiperij B, El-Agnaf OM, Engelborghs S, Herukka SK, et al. The utility of alpha-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomark Med 2016;10:19-34.
106. Hampel H, O’Bryant SE, Castrillo JI, Ritchie C, Rojkova K, et al. Precision medicine - the golden gate for detection, treatment and prevention of Alzheimer’s disease. J Prev Alzheimers Dis 2016;3:243-59.
107. Hampel H, O’Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 2018;14:639-52.
108. Milne R, Bunnik E, Diaz A, Richard E, Badger S, et al. Perspectives on communicating biomarker-based assessments of Alzheimer’s disease to cognitively healthy individuals. J Alzheimers Dis 2018;62:487-98.
109. Bunnik EM, Richard E, Milne R, Schermer MHN. On the personal utility of Alzheimer’s disease-related biomarker testing in the research context. J Med Ethics 2018;44:830-4.
110. Milne R, Diaz A, Badger S, Bunnik E, Fauria K, et al. At, with and beyond risk: expectations of living with the possibility of future dementia. Sociol Health Illn 2018;40:969-87.
